TEMPEST THERAPEUTICS INC. - COMMON STOCK

Tempest Presents Promising Preclinical Data on Two Oncology Programs at the 2022 AACR Annual Meeting

08 4 2022 12:00:00 提供 Nasdaq GlobeNewswire

Tempest Reports Year End 2021 Financial Results and Provides Business Update

29 3 2022 15:00:00 提供 Nasdaq GlobeNewswire

Tempest to Present at the 32nd Annual Oppenheimer Healthcare Conference

10 3 2022 07:00:01 提供 Nasdaq GlobeNewswire

Tempest to Present Two Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting

08 3 2022 15:30:00 提供 Nasdaq GlobeNewswire

Tempest to Present at the 11th Annual SVB Leerink Healthcare Conference

09 2 2022 07:00:03 提供 Nasdaq GlobeNewswire

Tempest Announces First Patient Dosed with TPST-1495 in Combination with Pembrolizumab

18 11 2021 07:00:02 提供 Nasdaq GlobeNewswire

Tempest Presents Data Supporting the Dual Mechanism of TPST-1495 as an Optimal Approach for Targeting the Prostaglandin Pathway in Cancer

12 11 2021 06:00:02 提供 Nasdaq GlobeNewswire

Tempest Reports Third Quarter 2021 Financial Results and Provides Corporate Highlights

10 11 2021 15:05:01 提供 Nasdaq GlobeNewswire

Tempest to Present at Two Upcoming Investor Conferences in November

09 11 2021 07:00:02 提供 Nasdaq GlobeNewswire

Tempest Further Bolsters Patent Portfolio with Issuance of Multiple Patents for TPST-1495

08 11 2021 07:00:01 提供 Nasdaq GlobeNewswire

Tempest Announces Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

01 10 2021 07:00:01 提供 Nasdaq GlobeNewswire

Tempest Announces First Patient Dosed in Randomized Study Evaluating TPST-1120 in First-Line Regimen for Hepatocellular Carcinoma in Clinical Collaboration with Roche

20 9 2021 07:00:02 提供 Nasdaq GlobeNewswire

Tempest Enters into Exclusive License Agreement with the University of California for Novel Cancer Target

13 9 2021 07:00:01 提供 Nasdaq GlobeNewswire

Tempest to Present at Upcoming Investor Conferences

09 9 2021 15:01:00 提供 Nasdaq GlobeNewswire